Knee Osteoarthritis Reframed as Joint Aging — What Geroscience Changes About Treatment
A geroscience lens on knee OA reveals why cellular senescence and inflammaging drive the disease — and which therapies actually address joint healthspan.
Summary
Knee osteoarthritis (KOA) is increasingly understood not as simple wear-and-tear but as a manifestation of joint aging — driven by cellular senescence, chronic low-grade inflammation, mitochondrial dysfunction, and impaired tissue repair. This narrative review from Semmelweis University and Harvard applies a geroscience framework to evaluate the full spectrum of non-surgical KOA treatments. Exercise, weight loss, and patient education remain the strongest interventions, with benefits extending beyond pain relief to systemic inflammation and metabolism. Standard drugs and joint injections manage symptoms but don't slow aging biology. Emerging approaches like platelet-rich plasma and stem cell therapies show promise but lack consistent long-term data. Genicular nerve ablation and genicular artery embolization target specific pain and vascular mechanisms, though evidence for the latter remains mixed. The authors call for future trials that distinguish symptom relief from genuine modification of joint aging.
Detailed Summary
Knee osteoarthritis affects hundreds of millions globally and is a leading cause of late-life pain and disability. Yet the dominant mechanical model — joints simply wearing out — fails to explain why aging is the single largest risk factor. This review from researchers at Semmelweis University, Harvard Medical School, and the University of Oklahoma reframes KOA as a phenotype of joint aging, shaped by the same biological hallmarks driving systemic aging: cellular senescence, inflammaging, mitochondrial dysfunction, synovial inflammation, and vascular remodeling.
The authors conducted a structured search of PubMed/MEDLINE and Embase covering January 2010 to May 2026, synthesizing randomized trials, meta-analyses, clinical guidelines, and high-quality observational studies across the full non-surgical treatment landscape.
Core lifestyle interventions — weight reduction, structured exercise, and patient education — emerge as the most robustly supported joint healthspan strategies. Their benefits are not merely symptomatic; they favorably modulate systemic inflammation and metabolic pathways that underpin aging biology. Standard pharmacologic agents (NSAIDs, intra-articular corticosteroids) and hyaluronic acid injections remain useful symptom modulators but offer no meaningful modification of the underlying aging process.
Biological therapies including platelet-rich plasma, autologous conditioned serum, and mesenchymal stromal/stem cell approaches are biologically compelling given their potential to counter senescent microenvironments, but heterogeneous protocols and insufficient long-term structural outcome data limit clinical confidence. Genicular nerve ablation can extend functional longevity through durable pain control. Genicular artery embolization targets synovitis and pathological hypervascularity — biological features consistent with the inflammaging model — but sham-controlled trial results remain inconsistent.
The central contribution of this review is its call for a phenotype-informed, geroscience-guided approach: matching treatment to the dominant biological driver in each patient (synovitis, senescence, mechanical overload) rather than applying a one-size-fits-all protocol. Future trials must differentiate symptom relief from true disease modification at the level of joint aging biology.
Key Findings
- Exercise, weight loss, and education are the strongest joint healthspan interventions, with systemic anti-inflammatory and metabolic benefits.
- KOA should be treated as a joint aging phenotype driven by senescence and inflammaging, not purely mechanical wear.
- Platelet-rich plasma and stem cell therapies are promising but lack consistent long-term structural evidence.
- Genicular artery embolization is biologically plausible for synovitis-dominant KOA but sham-controlled trial results are inconsistent.
- Future trials must distinguish symptom relief from genuine modification of joint aging biology.
Methodology
This is a narrative review covering PubMed/MEDLINE and Embase from January 2010 to May 2026. Included study types were randomized trials, meta-analyses, clinical guidelines, position statements, and high-quality observational studies. A geroscience-guided, phenotype-informed framework was used to organize and interpret the evidence.
Study Limitations
This is a narrative rather than systematic review, introducing potential selection bias in the literature included. The summary is based on the abstract only, so full methodological details, evidence tables, and subgroup analyses are not available. Heterogeneity in biological therapy protocols and inconsistent outcome measures across trials limit strength of conclusions for PRP, stem cells, and GAE.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: